AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
22 Marzo 2023 - 2:00PM
Business Wire
AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they
have entered into a strategic collaboration to identify optimal
clinical candidates for up to three infectious disease targets
selected by RQ Bio, including influenza and cytomegalovirus (CMV).
The partnership aims to provide long-lasting infectious diseases
medicines to high-risk patients by bringing together RQ Bio’s
expertise in infectious diseases and viral evolution with
AbCellera’s discovery engine for finding rare, highly potent
antibodies.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230320005682/en/
“We believe antibody therapies have an important role to play in
protecting the most clinically at-risk populations from infectious
diseases,” said Carl Hansen, Ph.D., founder and CEO of AbCellera.
“AbCellera’s discovery engine complements RQ Bio’s capabilities and
provides a technology advantage that we believe will help bring new
medicines for infectious disease to patients faster.”
“Both RQ Bio and AbCellera have proven track records in
developing infectious disease medicines that have a rapid impact on
vulnerable patients,” said Hugo Fry, CEO of RQ Bio. “We look
forward to working with AbCellera to quickly advance our pipeline
of infectious disease medicines for people who are at risk of
severe disease or death from viral infections.”
Under the terms of the agreement, RQ Bio has the right to
develop and commercialize therapeutic antibodies resulting from the
collaboration. AbCellera will receive research payments and is
eligible to receive downstream clinical and regulatory milestone
payments and royalties on net sales of products.
About AbCellera Biologics Inc. AbCellera is breaking the
barriers of conventional antibody drug discovery to bring better
medicines to patients, sooner. AbCellera’s engine integrates expert
teams, technology, and facilities with the data science and
automation needed to propel antibody-based medicines from target to
clinic in nearly every therapeutic area with precision and speed.
AbCellera provides innovative biotechs and leading pharmaceutical
companies with a competitive advantage that empowers them to move
quickly, reduce cost, and tackle the toughest problems in drug
development. For more information, please visit
www.abcellera.com.
About RQ Bio RQ Bio’s mission is to develop medicines
based on potent broad-spectrum monoclonal antibodies (mAbs) to
provide instant and long-lasting immunity for vulnerable people at
risk of severe disease or death from current and future variants of
viral infections. RQ Bio has achieved this by combining innovative
excellence in core areas to create a smarter approach to antibody
generation. RQ Bio has multiple sources of leads and a deep
collaboration with the University of Oxford. The Company was
founded by scientific experts, which worked to build a community of
infectious disease antibody experts focussed on the development of
rapid and efficient delivery of highly potent neutralising
antibodies to help support the UK COVID-19 response. For more
information, please visit www.rqbiotechnology.com / LinkedIn.
AbCellera Forward-Looking Statements This press release
contains forward-looking statements, including statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are
based on management’s current beliefs and assumptions and on
information currently available to management. All statements
contained in this release other than statements of historical fact
are forward-looking statements, including statements regarding our
ability to develop, commercialize and achieve market acceptance of
our current and planned products and services, our research and
development efforts, and other matters regarding our business
strategies, use of capital, results of operations and financial
position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230320005682/en/
AbCellera: Media: Jessica Yingling, Ph.D.;
media@abcellera.com, +1(236)521-6774 Business Development: Murray
McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005 Investor
Relations: Josephine Hellschlienger, Ph.D.; ir@abcellera.com,
+1(778)729-9116
RQ Bio: media@rqbiotechnology.com
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Lug 2023 a Lug 2024